Table 2.
Complications after conversion to belatacept.
| Total Patients N = 453 |
Early Conversion a N = 121 |
Late Conversion a N = 332 |
p-Value | |
|---|---|---|---|---|
| Renal complications | ||||
| Kidney allograft failure n (%) | 42 (9.3) | 23 (19.0) | 19 (5.7) | <0.001 |
| Rejection post-conversion n (%) | 24 (5.3) | 10 (8.3) | 14 (4.2) | 0.143 |
| Viral complications | ||||
| CMV DNAemia n (%) | 74 (16.9) | 37 (31.6) | 37 (11.5) | <0.001 |
| CMV disease n (%) | 22 (4.8) | 14 (11.6) | 8 (2.4) | <0.001 |
| Time between belatacept conversion to CMV disease—months | 10.7 ± 9 | 9.6 ± 10 | 12.7 ± 8 | 0.188 |
| EBV DNAemia n (%) | 133 (36.0) | 13 (14.8) | 120 (42.7) | <0.001 |
| BK virus DNAemia n (%) | 6 (2.0) | 4 (7.2) | 2 (0.8) | 1 |
| BK nephropathy n (%) | 0 | 0 | 0 | - |
| JC Virus n (%) | 2 (0.4) | 2 (1.6) | 0 | 0.121 |
| VZV n (%) | 5 (1.1) | 2 (1.6) | 3 (0.9) | 0.610 |
| Bacterial complications | ||||
| Tuberculosis n (%) | 2 (0.4) | 1 (0.8) | 1 (0.3) | 0.458 |
| Fungal complications | ||||
| Pneumocystis pneumonia n (%) | 13 (2.8) | 6 (4.9) | 7 (2.1) | 0.557 |
| Aspergillosis pneumonia n (%) | 2 (0.4) | 2 (1.6) | 0 | 0.121 |
| Other complications | ||||
| Death n (%) | 22 (4.8) | 10 (8.3) | 12 (3.6) | 0.073 |
Results are expressed according to N (%). Missing data are not taken into account for the calculation of percentages. CMV, Cytomegalovirus; EBV, Epstein–Barr virus; VZV: varicella zoster virus. a Early conversion was considered as belatacept conversion before 6 months after kidney transplantation, and later conversion was >6 months after transplantation.